List of Excipients in Branded Drug ZOHYDRO ER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Persion Pharmaceuticals LLC	ZOHYDRO ER	hydrocodone bitartrate	65224-310	AMMONIO METHACRYLATE COPOLYMER TYPE B
Persion Pharmaceuticals LLC	ZOHYDRO ER	hydrocodone bitartrate	65224-310	FD&C BLUE NO. 1
Persion Pharmaceuticals LLC	ZOHYDRO ER	hydrocodone bitartrate	65224-310	FD&C RED NO. 3
Persion Pharmaceuticals LLC	ZOHYDRO ER	hydrocodone bitartrate	65224-310	FD&C RED NO. 40
Persion Pharmaceuticals LLC	ZOHYDRO ER	hydrocodone bitartrate	65224-310	FERRIC OXIDE RED
Persion Pharmaceuticals LLC	ZOHYDRO ER	hydrocodone bitartrate	65224-310	FERRIC OXIDE YELLOW
Persion Pharmaceuticals LLC	ZOHYDRO ER	hydrocodone bitartrate	65224-310	FERROSOFERRIC OXIDE

Zohydro ER Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Zohydro ER is an extended-release hydrocodone bitartrate capsule developed for severe, continuous pain requiring around-the-clock opioid treatment. Its commercial opportunity is defined less by novel active-ingredient protection than by controlled-release technology, dose flexibility, abuse-deterrence positioning, supply reliability, and potential reformulation. The product’s key technical constraint is that its original formulation was not labeled as abuse-deterrent, leaving room for excipient-driven differentiation in future hydrocodone extended-release products.

What is Zohydro ER and how does its formulation work?

Zohydro ER contains hydrocodone bitartrate in extended-release capsules dosed every 12 hours. The product was approved by the U.S. Food and Drug Administration in October 2013 under NDA 202880 for severe pain requiring daily, around-the-clock, long-term opioid treatment.[1]

The commercial formulation uses multiparticulate extended-release technology rather than an immediate-release hydrocodone tablet. The formulation is designed to slow hydrocodone release through coated particles or beads contained in a hard gelatin capsule. This design supports dose strengths from 10 mg to 50 mg and permits administration by swallowing the capsule intact.

The FDA labeling states that Zohydro ER does not have abuse-deterrent properties.[1] That point is central to both excipient strategy and market positioning. A formulation that controls release after tampering, resists crushing, or reduces opioid extraction could compete more effectively in the extended-release opioid market, although abuse-deterrence claims require FDA review and supporting laboratory, pharmacokinetic, and potentially clinical evidence.[2]

What excipients are relevant to Zohydro ER?

Public labeling identifies inactive ingredients used in the capsule and extended-release multiparticulate system. The formulation platform generally relies on excipient classes with established roles in coating, drug release, particle integrity, capsule manufacture, and powder flow.

Excipient class	Technical function	Commercial relevance
Cellulosic polymers	Matrix formation, film coating, viscosity control	Supports predictable release and broad supplier availability
Ethylcellulose or related water-insoluble polymers	Diffusion-controlled release coating	Enables release-rate tuning and multiparticulate manufacture
Hypromellose	Film formation and controlled hydration	Useful for release modulation and capsule-fill robustness
Microcrystalline cellulose	Pellet or bead substrate, diluent, mechanical support	Supports scalable multiparticulate processing
Lactose or other fillers	Bulking and dose uniformity	Low-cost, established supply chain
Talc and silicon dioxide	Anti-tacking, glidant, coating-process support	Improves manufacturing throughput
Magnesium stearate	Lubrication	Supports capsule-filling operations
Gelatin and titanium dioxide	Capsule shell construction and opacity	Standard capsule-shell components
Colorants	Strength identification and product differentiation	Supports medication error reduction

The critical value is not any single excipient. It is the interaction between particle size, coating thickness, polymer permeability, porosity, drug loading, capsule fill weight, and dissolution conditions.

How can excipients improve a Zohydro ER-type product?

A reformulated hydrocodone extended-release product could pursue four technical objectives: stronger release control, improved abuse resistance, lower manufacturing cost, and more consistent pharmacokinetics.

Release-rate optimization

The principal formulation opportunity is to create a multiparticulate system with less sensitivity to gastrointestinal pH, food effects, agitation, and alcohol exposure. Polymer coatings can be adjusted by:

• changing the ratio of water-soluble to water-insoluble polymers;
• modifying coating thickness;
• incorporating pore formers;
• changing pellet diameter;
• applying multiple functional coating layers; and
• using a matrix-plus-coating architecture.

A multiparticulate system can reduce the clinical impact of dose dumping from an individual damaged unit because the total dose is distributed across many particles. That advantage depends on the specific design and cannot be assumed from multiparticulate architecture alone.

Abuse-deterrent performance

The largest strategic opportunity is an abuse-deterrent formulation. Potential excipient approaches include:

• high-viscosity polymers that form a gel when crushed and mixed with liquid;
• hard, waxy matrices that resist milling;
• ion-exchange or sequestration systems that reduce opioid extraction;
• pH-responsive polymers that limit hydrocodone release across common solvents;
• thermoplastic or high-melting excipients that increase manipulation difficulty; and
• combinations of crush-resistant pellets with extraction-resistant coatings.

FDA’s abuse-deterrent guidance distinguishes physical and chemical manipulation resistance, pharmacokinetic effects, and actual abuse-deterrence outcomes.[2] A product that is difficult to crush may still permit extraction or oral abuse. Commercial claims therefore depend on the evidence package, not on the presence of a particular polymer.

Capsule-opening and sprinkle performance

Patients with swallowing difficulty may benefit from capsules that can be opened and sprinkled over soft food without destroying extended release. This creates an opportunity for excipient engineering around:

• bead integrity after capsule opening;
• minimal adhesion to food;
• palatability;
• resistance to chewing;
• dose uniformity across the food vehicle; and
• stability after short-term exposure to moisture.

Any sprinkle presentation would require product-specific labeling and evidence. It cannot be created through a manufacturing change alone.

Supply-chain resilience

Extended-release opioid products require qualified suppliers for polymers, pellet substrates, coating systems, capsule shells, and colorants. Commercially attractive excipient strategies reduce dependence on a single supplier and avoid excipients with:

• limited global manufacturing capacity;
• inconsistent particle-size distributions;
• high batch-to-batch viscosity variation;
• regulatory restrictions in target markets;
• high residual-solvent burdens; or
• poor compatibility with continuous coating equipment.

A dual-source strategy is especially valuable for coating polymers and capsule shells because changes in substitution level, viscosity grade, or particle morphology can alter dissolution.

What commercial opportunities exist for excipient suppliers?

The opportunity is strongest in enabling technologies rather than commodity fillers.

High-value excipient categories

Opportunity	Buyer need	Potential product offering
Abuse-deterrent polymers	Resistance to crushing and extraction	High-viscosity or pH-responsive polymer systems
Controlled-release coating platforms	Stable 12-hour release	Prequalified coating premixes
Multiparticulate substrates	Uniform bead manufacture	Narrow-size-distribution starter cores
Taste-masking systems	Sprinkle and pediatric-adjacent use cases	Functional coatings with low sensory impact
Continuous-processing excipients	Lower manufacturing cost	Flow-optimized, low-dust grades
Analytical support	Faster formulation selection	Dissolution and extraction-screening services
Dual-source excipient systems	Supply continuity	Equivalent grades with regulatory bridging packages

Excipient suppliers can create switching costs by providing a complete technical package: formulation design, coating parameters, dissolution methods, extractables data, stability support, and regulatory documentation.

The best commercial position is an excipient platform that solves both technical and regulatory problems. A polymer that improves crush resistance but creates food-effect variability has limited value. A coating system that works in development but cannot be scaled under cGMP conditions also has weak commercial utility.

What FDA exclusivity and Orange Book protections affect Zohydro ER?

Zohydro ER’s commercial protection has several layers:

Protection	Relevance
NDA approval	Establishes the approved hydrocodone extended-release product
Regulatory exclusivity	Protects defined approval-related rights for a limited period
Formulation patents	May cover controlled-release particles, coatings, or dosage forms
Method-of-use patents	May cover treatment of severe chronic pain or dosing regimens
Manufacturing patents	May cover bead formation, coating, or release-control processes
Trademark rights	Protect the Zohydro ER commercial identity
Controlled-substance regulation	Creates manufacturing, distribution, inventory, and security barriers

Zohydro ER did not receive new chemical entity exclusivity because hydrocodone had previously been approved in other products. Its regulatory protection therefore depended on the specific approval basis and any applicable three-year exclusivity for new clinical investigations, along with patent rights.[1,3]

The FDA Orange Book should be used to confirm the current status of listed patents, delisting activity, product discontinuation status, and any approved generic applications.[3] Patent listings can change through expiration, correction, litigation, or regulatory action. A formulation developer should not rely on historical patent summaries without checking the current Orange Book record and prosecution history.

What patents protect Zohydro ER-type formulations?

The relevant patent estate is likely to include claims directed to:

1. hydrocodone extended-release dosage forms;
2. multiparticulate beads or pellets;
3. polymer-coated drug particles;
4. specified dissolution profiles;
5. twice-daily dosing;
6. methods for treating chronic pain;
7. manufacturing processes; and
8. combinations of release-controlling excipients.

The commercial strength of these patents depends on claim scope and validity, not the number of patent documents. A narrow patent covering a specific polymer ratio may be easy to design around. A patent covering a broad functional release profile may have greater blocking potential but face greater validity risk.

How strong is the patent estate for an excipient-based competitor?

An excipient-based competitor can reduce infringement risk by changing:

• the release mechanism;
• the polymer family;
• the coating sequence;
• the bead-size distribution;
• the drug-loading range;
• the capsule architecture;
• the dissolution profile; or
• the manufacturing process.

Design-around analysis must evaluate claim construction, prosecution-history estoppel, equivalents risk, and jurisdiction-specific enforcement. A different excipient is not automatically a non-infringing formulation if the patent claims the functional result or a broad combination.

When did Zohydro ER lose exclusivity, and what generic entry risks exist?

The principal regulatory exclusivity period expired years after the 2013 approval, while patent-based barriers could extend beyond regulatory exclusivity. Generic applicants may challenge listed patents through Paragraph IV certifications under the Hatch-Waxman Act.[4]

Potential generic entry routes include:

• an ANDA for the same extended-release capsule;
• a Paragraph IV challenge to formulation patents;
• a Section viii statement carving out protected methods of use;
• a 505(b)(2) application using a modified release system; and
• a reformulated hydrocodone product with distinct abuse-deterrent properties.

For an ANDA sponsor, the major technical risks are bioequivalence, alcohol-dose-dumping studies, food-effect performance, dissolution matching, and control of particle-size distribution. For the innovator, the principal defense is a patent estate covering the release architecture rather than only the identity of individual excipients.

What patent litigation and settlement issues affect commercial planning?

Paragraph IV litigation can delay generic launch through a 30-month stay when statutory conditions are met.[4] Settlement agreements may establish an authorized generic launch date, a licensed entry date, or restrictions on formulation and manufacturing. The business impact depends on whether the settlement permits:

• an authorized generic;
• an early generic launch;
• a competing abuse-deterrent formulation;
• a license to specific manufacturing technology; or
• entry only after patent expiration.

Public litigation records should be reviewed for the NDA holder, patent owners, ANDA applicants, asserted patent numbers, claim construction decisions, invalidity findings, and settlement terms. A litigation outcome against one patent does not necessarily eliminate risk from unasserted patents or later-issued continuation patents.

Which companies are positioned to challenge or replace Zohydro ER?

The competitive set includes:

• generic manufacturers with opioid extended-release capabilities;
• specialty pharmaceutical companies with abuse-deterrent platforms;
• manufacturers of hydrocodone combination products;
• companies developing non-opioid chronic-pain therapies; and
• excipient suppliers licensing controlled-release technology.

The most credible competitor is not necessarily the lowest-cost generic. A product with abuse-deterrent labeling, reliable twice-daily exposure, lower tampering risk, and strong supply continuity may command a differentiated position despite higher manufacturing cost.

Potential competitors also include Hysingla ER, an extended-release hydrocodone product with abuse-deterrent labeling, and other extended-release opioids such as Xtampza ER and OxyContin, although these products use different active ingredients or delivery technologies.[5-7]

How does Zohydro ER compare with abuse-deterrent extended-release opioids?

Attribute	Zohydro ER	Abuse-deterrent competitors
Active ingredient	Hydrocodone bitartrate	Hydrocodone or oxycodone, depending on product
Dosage form	Extended-release capsule	Capsule or tablet
Abuse-deterrent labeling	No	Present for qualifying products
Excipient opportunity	Reformulation and design-around	Incremental improvement and cost reduction
Main technical risk	Dose dumping and tampering perception	Manufacturing complexity and evidence burden
Commercial differentiation	Dose flexibility and hydrocodone positioning	Abuse-deterrent labeling and payer differentiation
Generic threat	Formulation and patent challenges	Complex bioequivalence and formulation patents

The most commercially attractive strategy is a hydrocodone extended-release product that combines capsule flexibility with abuse-deterrent performance. Its value would depend on FDA labeling, clinical utility, payer acceptance, and the absence of a materially superior competing opioid.

What revenue exposure and licensing opportunities exist?

Revenue exposure depends on whether Zohydro ER has active commercial sales, an authorized generic, or licensing arrangements in the relevant market. The public product history includes ownership and commercialization changes involving Zogenix and Pernix, making chain-of-title review important for licensing and diligence.[8]

Commercial opportunities include:

• licensing a bead-coating platform to an NDA holder;
• supplying qualified polymer systems;
• acquiring or partnering around an ANDA;
• developing an authorized generic;
• licensing manufacturing know-how;
• supplying a reformulated abuse-deterrent product; and
• using the technology in non-opioid extended-release products.

The strongest licensing asset is a validated formulation platform that can be transferred across active ingredients. A hydrocodone-only formulation has a smaller addressable market and greater regulatory sensitivity. A technology that supports oxycodone, hydrocodone, methylphenidate, or other controlled-release drugs has broader value.

What geographic coverage matters?

The U.S. is the central market because Zohydro ER was approved by FDA and hydrocodone controls are highly specific to U.S. regulation. International commercialization would require separate approvals, narcotics permits, import controls, pharmacovigilance systems, and local patent analysis.

Key geographic diligence points include:

• U.S. Orange Book status;
• Canadian and European authorization status;
• national patent family members;
• supplementary protection or pediatric extensions;
• controlled-substance import rules;
• local excipient acceptance;
• manufacturing-site approvals; and
• language and labeling requirements.

A U.S. formulation patent may have limited value if corresponding claims were not granted in Europe, Canada, Japan, or other target markets.

Key Takeaways

• Zohydro ER is a hydrocodone bitartrate extended-release capsule approved in 2013.
• Its original labeling did not identify abuse-deterrent properties.
• The principal excipient opportunity is a multiparticulate or polymer system that improves tamper resistance without creating food-effect or dose-dumping problems.
• Excipient suppliers can capture value through integrated coating systems, analytical support, scale-up assistance, and dual-source regulatory packages.
• Generic entry risk depends on formulation patents, Orange Book listings, Paragraph IV challenges, bioequivalence, and dissolution performance.
• A reformulated hydrocodone product with abuse-deterrent labeling would have greater commercial differentiation than a conventional generic.
• Licensing value is higher for a transferable controlled-release platform than for a hydrocodone-only formulation.
• Current patent, litigation, ownership, and commercial status must be assessed from the latest FDA, USPTO, court, and corporate records before investment or licensing decisions.

FAQs

Can a Zohydro ER generic use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the product meets applicable safety, pharmaceutical-equivalence, bioequivalence, dissolution, and labeling requirements. Different excipients can create new patent and regulatory risks if they materially alter release behavior.

Does multiparticulate technology automatically make Zohydro ER abuse-deterrent?

No. Multiparticulate design may improve dose distribution and release control, but FDA abuse-deterrent labeling requires product-specific evidence against relevant manipulation methods.[2]

Can an excipient supplier patent a Zohydro ER reformulation?

Yes. Patentable subject matter may include a novel polymer combination, particle architecture, dissolution profile, manufacturing process, or abuse-deterrent performance, provided the statutory requirements for patentability are met.

What is the most valuable excipient for a hydrocodone extended-release product?

There is no universal best excipient. Commercial value generally comes from a validated system combining release-controlling polymers, mechanically robust particles, scalable coating operations, and predictable in vitro and in vivo performance.

Could a 505(b)(2) product compete with a Zohydro ER generic?

Yes. A 505(b)(2) applicant could pursue a modified extended-release system, abuse-deterrent formulation, new dosage form, or other change supported by published data and bridging studies. Patent and exclusivity protections would still need to be evaluated.

References

1. U.S. Food and Drug Administration. (2013). Zohydro ER hydrocodone bitartrate extended-release capsules: Prescribing information and approval materials.
2. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
5. U.S. Food and Drug Administration. (2014). Hysingla ER hydrocodone bitartrate extended-release tablets: Prescribing information.
6. U.S. Food and Drug Administration. (2016). Xtampza ER oxycodone extended-release capsules: Prescribing information.
7. U.S. Food and Drug Administration. (2010). OxyContin oxycodone hydrochloride extended-release tablets: Prescribing information.
8. Pernix Therapeutics Holdings, Inc. (2017-2020). Securities filings and corporate reports.